Table 2.
PFT before HCT
| All n = 83 | Mean Difference from Reference Population (1-sided t-test) | Immune-Deficiency n = 13 | Malignant Disease Pretreated with Chemotherapy n = 41 | Bone Marrow Disease, Inborn Errors of Metabolism No Pretreatment n = 29 | Difference between Disease Groups (ANOVA) | |
|---|---|---|---|---|---|---|
| FEV1 (% pred) | 82.7 (SD 11.5) | −17.3 [95% CI, −20.5-14.1; P < .0001] | 83.5 (12.9) | 81.3 (10.1) | 84.3 (12.6) | NS |
| FVC (% pred) | 87.8 (SD 14.1) | −12.2 [95% CI, −16.2-8.2; P < .0001] | 91.5 (14.6) | 86.3 (12.7) | 88.1 (15.7) | NS |
| TLC (% pred) | 86.9 (SD 10.2) | −14.5 [95% CI, −17.9-11.1; P < .0001] | 92.2 (8.3) | 83.8 (10.8) | 84.5 (7.6) | NS |
| RV/TLC | 25.2 (SD 5.7) | 25.4 (5.8) | 23.6 (4.9) | 27.5 (6.0) | NS | |
| TLCO (% pred) | 81.9 (SD 18.5) | −18 [95% CI, −25.8-10.4; P < .0001] | 85.7 (21.6) | 81.0 (19.8) | 81.2 (13.2) | NS |
| Abnormal PFT (<80% pred or RV/TLC > 25) | 8 patients (62%) | 28 patients (68%) | 19 patients (65%) |
FEV1 indicates forced expiratory volume in 1 second; % pred, percentage of predicted value; 95% CI, 95% confidence interval; NS, not significant; FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; TLCO, lung diffusion capacity for CO.
Mean values and SD in all patients, compared with reference population, mean values and SD per disease group, and comparison between disease groups.